Jagsonpal Pharmaceuticals Ltd Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Standalone Quarterly Results

Jun'26

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Jun 2026 is 28.08% vs -11.99% in Mar 2026

Standalone Net Profit

QoQ Growth in quarter ended Jun 2026 is 50.57% vs -20.00% in Mar 2026

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Jun 2026 is 54.48% vs -31.45% in Mar 2026

Interest

QoQ Growth in quarter ended Jun 2026 is 0.00% vs -3.85% in Mar 2026

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Jun 2026 has improved from Mar 2026

Compare Quarterly Results Of Jagsonpal Pharma With

Select Peers

Figures in Cr

Standalone Quarterly Results

Change(INR)

Change(%)

Net Sales

82.23

109.88

-27.65

-25.16%

Other Operating Income

0.00

Total Operating income

82.23

109.88

-27.65

-25.16%

Raw Material Cost

4.87

36.42

-31.55

-86.63%

Purchase of Finished goods

26.05

2.32

23.73

1,022.84%

(Increase) / Decrease In Stocks

-2.29

-3.85

1.56

40.52%

Employee Cost

22.78

18.32

4.46

24.34%

Power Cost

0.00

Manufacturing Expenses

-0.01

0.00

-0.01

Selling and Distribution Expenses

0.00

Other Expenses

13.59

34.83

-21.24

-60.98%

Total Expenditure (Excl Depreciation)

64.99

88.04

-23.05

-26.18%

Operating Profit (PBDIT) excl Other Income

17.24

21.84

-4.60

-21.06%

Other Income

2.83

6.10

-3.27

-53.61%

Operating Profit (PBDIT)

20.07

27.94

-7.87

-28.17%

Interest

0.25

2.77

-2.52

-90.97%

Exceptional Items

0.00

9.07

-9.07

-100.00%

Gross Profit (PBDT)

19.82

34.24

-14.42

-42.11%

Depreciation

2.14

5.08

-2.94

-57.87%

Profit Before Tax

17.68

29.16

-11.48

-39.37%

Tax

4.49

7.59

-3.10

-40.84%

Provisions and contingencies

0.00

Profit After Tax

13.19

21.57

-8.38

-38.85%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

13.19

21.57

-8.38

-38.85%

Equity Capital

13.17

14.34

-1.17

-8.16%

Face Value

2.00

5.00

0.00

Reserves

0.00

Earnings per share (EPS)

2.00

7.52

-5.52

-73.40%

Diluted Earnings per share

1.98

5.21

-3.23

-62.00%

Operating Profit Margin (Excl OI)

20.97%

19.88%

0.00

1.09%

Gross Profit Margin

24.10%

31.16%

0.00

-7.06%

PAT Margin

16.04%

19.63%

0.00

-3.59%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 82.23 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is 28.08% vs -11.99% in Mar 2026

YoY Growth in quarter ended Jun 2026 is 8.76% vs 23.06% in Jun 2025

Quarterly - Standalone Net Profit

Standalone Net Profit 13.19 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is 50.57% vs -20.00% in Mar 2026

YoY Growth in quarter ended Jun 2026 is 22.13% vs 102.63% in Jun 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 17.24 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is 54.48% vs -31.45% in Mar 2026

YoY Growth in quarter ended Jun 2026 is 21.32% vs 38.77% in Jun 2025

Quarterly - Interest

Interest 0.25 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is 0.00% vs -3.85% in Mar 2026

YoY Growth in quarter ended Jun 2026 is 0.00% vs 13.64% in Jun 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 20.97%

in Jun 2026

Figures in %

QoQ Growth in quarter ended Jun 2026 has improved from Mar 2026

YoY Growth in quarter ended Jun 2026 has improved from Jun 2025